Introduction
The delivery of corrective or destructive genes via adenovirus is an attractive method for gene therapy of cancer. Adenovirus enters the cell by binding to the coxsackie and adenovirus receptor (CAR), which is followed by endocytosis and transgene expression. 1 In vitro, adenoviral gene transfer is efficient in many cell types but the success of gene therapy in vivo is still hampered by inefficient delivery and expression of transgenes. In addition, tumors may have reduced CAR expression, which would further contribute to poor adenoviral transducibility and transgene expression. [2] [3] [4] [5] In an effort to enhance the effectiveness of cancer gene therapy, adenoviral gene therapy has been combined with chemotherapy. Encouraging results have been obtained in clinical trials using an adenovirus expressing p53 in combination with systemic cisplatin and 5-fluorouracil. [6] [7] [8] Gemcitabine has also successfully been combined with adenoviral gene therapy in animals. 9, 10 Some agents, including the DNA damaging agent etoposide and a new class of chemotherapeutic agents known as histone deacetylase inhibitors (HDACi) increase adenoviral transgene expression, thereby potentially lowering the amount of adenovirus required to achieve a therapeutic response. [11] [12] [13] [14] The mechanism by which HDACi's increase adenoviral transgene expression has been attributed to restoration of CAR expression. [12] [13] [14] The goal of this study was to determine which chemotherapeutic agents would be suitable for combination with gene therapy in prostate cancer. Prostate cancer remains a leading cause of cancer death among American men. The American Cancer Society estimates that over 27 000 men will die of the disease in 2006. Advanced prostate cancer is currently not curable and numerous clinical trials are in progress (www.clinicaltrials.gov). One molecule that has recently entered a Phase I clinical trial at Genentech Inc. is a recombinant form of the proapoptotic death ligand tumor necrosis factor-related apoptosis inducing ligand (TRAIL) also known as Apo2L. TRAIL binds to specific surface receptors and can selectively induce apoptosis in many malignant cells by activating the caspase cascade. 15 Unfortunately, prostate cancer cells are relatively resistant to the proapoptotic effects of soluble recombinant TRAIL. 16 We have previously shown that an adenovirus expressing fulllength membrane bound TRAIL can induce apoptosis in prostate cancer cells but the infectious units required per cell were relatively high and selectivity for malignant cells was lost. 16 In this study, we show that two HDACi currently in clinical trials 17 enhance infectivity and transgene expression in the malignant prostate cancer cell line LNCaP but not in normal prostate epithelial cells. Combination of HDAC inhibitors with a low dose of TRAIL-expressing adenovirus resulted in selective induction of apoptosis in LNCaP cells. These results suggest that combination of HDAC inhibitors with adenoviral TRAIL gene therapy may be a new therapeutic approach for the treatment of prostate cancer.
Materials and methods

Cell culture
LNCaP cells were purchased from the ATCC (Rockville, MD) and were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT) and antibiotics. Cultures of primary prostate epithelial cells (PrEC, Lot no. IF-1561 and CL-2555) were purchased from Clonetics and were maintained according to the manufacturer's instructions. Cells were maintained at 371C in 5% CO 2 atmosphere.
Adenoviral vectors
The adenoviral vectors Ad CMV GFP, Ad teton GFP and Ad teton TRAIL have previously been described. 16 Ad tetoff GFP-TRAIL was developed by cloning the TRAIL transgene into pEGFP-C1 (Clontech, Palo Alto, CA). The pEGFP-TRAIL plasmid was provided to the MUSC Vector Core Facility and Ad tetoff GFP-TRAIL generated as previously described for AdGFP-FasL. 18 Constructs were titered by counting GFP positive cells and titers were expressed as infectious units/ml (IU/ml). 
Viability assay
LNCaP cells were plated at 1 Â 10 4 cells/well on 96-well plates. After overnight plating, cells were treated with the indicated concentration of chemotherapeutic agents. Viability was determined 48 h after treatment initiation using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega) according to manufacturer's instructions. Absorbance was measured at 490 nm using a Fluostar Optima plate reader (BMG Labtech, Durham, NC) as described previously. 16 Western blotting Cells (3 Â 10 5 /well) were plated in six-well plates and treatments were initiated at 75% confluence. For vectors containing the TetOn promotor, 5 mg/ml doxycycline was added to the media. At 24 h post-treatment/infection, cells were scraped into media, pelleted and lysed in RIPA buffer (1% NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate (SDS) in PBS) containing mammalian protease and phosphatase inhibitor cocktails (Sigma). Lysates were cleared by centrifugation and Western blotting of the supernatant was performed as described previously. 16 The primary antibodies used were as follows: GFP (1:500, Clontech, cat no. 632377), TRAIL and PARP (1:1000, Santa Cruz Biotechnologies sc-7877 and sc-7150, respectively) anti-actin (1:2000 Sigma, A-2066), anti-caspase 3 (1:2000, Alexis, ALX-804-305-C100). Corresponding HRP-conjugated secondary antibodies were purchased from SantaCruz Biotechnologies.
Caspase-3/7 assay Cells were plated at 1 Â 10 4 /well in a 96-well plate on the day before treatment initiation. LNCaP and PrEC were infected at their respective ID 50 in growth medium, containing 5 mg/ml doxycycline for induction of transgenes under the tet-on promotor. Chemotherapy, if any, was given simultaneously. The Apo-ONE Homogeneous Caspase 3/7 Assay (Promega, Madison, WI) was performed 24 h post-infection/treatment initiation according to the manufacturer's instructions. Plates were read using a FluoStar plate reader (BMG Labtechnologies Inc., Durham, NC) with emission and excitation wavelengths of 485 nm and 520 nm, respectively.
Statistical analysis
The Student's t-test was used to determine statistical significance.
Results
HDAC inhibitors and doxorubicin increase transgene expression in LNCaP cells
In an effort to determine the effect of chemotherapy on adenoviral infection and transgene expression, LNCaP prostate cancer cells were infected with an adenovirus expressing GFP under control of the CMV promotor (Ad CMV GFP). LNCaP cells express CAR, the receptor used by adenovirus to enter the cells and the ID 50 was determined to be 5 IU/cell (Figure 1a (Figure 2f ). Doxorubicin treatment resulted in a dose-dependent and statistically significant increase of adenoviral infectivity up to 250 ng/ml when a 60% increase in GFP positive cells was detected (Figure 2c ). However, increased infectivity did not result in increased transgene expression, except at a concentration of 250 ng/ml (Figure 2c ). At higher doxorubicin concentrations, both infectivity and transgene expression dropped rapidly, which was paralleled by a loss in viability (Figure 2f ). The HDACi's MS-275 and depsipeptide increased infectivity up to twofold (Figure 2d and e) . In contrast to the other chemotherapeutic agents, HDACi's increased transgene expression up to 7-fold for MS-275 and 3.5-to 4.0-fold for depsipeptide, despite decreased viability (Figure 2d-f) .
HDAC inhibitors selectively increase infectivity, surface CAR, and transgene expression in LNCaP cells
To determine whether the effect of doxorubicin and HDACi's was selective for malignant cells, we compared changes in infectivity and GFP transgene expression in LNCaP and normal prostate epithelial cells (PrEC). Although LNCaP and PrEC had comparable surface level expression of CAR, a 14-fold higher concentration (70 IU/cell) of Ad CMV GFP was required to achieve the ID 50 in PrEC (Figure 1) . Therefore, in subsequent experiments LNCaP and PrEC were exposed to 5 or 70 IU/cell, respectively, to normalize for infection. The number of GFP positive cells nearly doubled when PrEC were treated with 250 ng/ml doxorubicin, which was significantly higher than the effect of doxorubicin on LNCaP cells (Figure 3a) . In contrast, MS-275 and . The effect of chemotherapeutic agents on infectivity as measured by GFP positivity was paralleled by surface CAR expression (Figure 3b) . Interestingly, the doxorubicin-mediated increase in infectivity and CAR expression did not result in increased transgene expression in PrEC (Figure 3c) . A dose of 250 ng/ml doxorubicin resulted in slightly increased GFP intensity only in LNCaP. Depsipeptide and MS-275 elevated GFP intensity in LNCaP several-fold without significant effects on PrEC (Figure 3c) .
In addition to flow cytometry, we also used western blotting to analyze the effect of doxorubicin, MS-275 and depsipeptide on transgene expression. As shown in Figure 4 , treatment with HDACi resulted in a several-fold increase in GFP expression following Ad CMV GFP infection. As our goal is to utilize chemotherapy in combination with TRAIL gene therapy, we also tested the effect of doxorubicin, MS-275 and depsipeptide on transgene expression following infection with Ad tetOn TRAIL-IRES-GFP. In this vector, TRAIL and GFP are expressed from a bi-cistronic message under control of the tet-On promotor as described previously. 16 As shown in Figure 4 , treatment with MS-275 or depsipeptide but not doxorubicin resulted in increased expression of both TRAIL and GFP in LNCaP cells. It is possible that the different effect of doxorubicin on transgene expression from Ad CMV GFP and Ad tetOn TRAIL-IRES-GFP is related to the promoters used in the constructs.
Combination of MS-275 or depsipeptide with AdTRAIL gene therapy selectively induces apoptosis in malignant
LNCaP cells Next, we tested how chemotherapy affects TRAIL gene therapy. Two adenoviral vectors expressing TRAIL, Ad tetOn TRAIL-IRES-GFP and Ad tetOff GFP-TRAIL, have been developed. Ad tetOff GFP-TRAIL expresses a GFP-TRAIL fusion protein under control of the tet-off promotor system. This vector was primarily developed to monitor subcellular expression of transgene expression but has similar activity when compared to Ad tetOn-TRAIL-IRES-GFP (data not shown). Western blotting reveals that some PARP and caspase-3 cleavage is detected following infection of LNCaP cells with Ad tetOff GFP-TRAIL (Figure 5a ). We noticed an increase in overall PARP expression but not PARP or caspase-3 cleavage when doxorubicin was added during Ad tetOff -GFP-TRAIL treatment. In contrast, co-treatment with MS-275 resulted in increased PARP and caspase-3 cleavage in Ad tetOff GFP-TRAIL-infected LNCaP cells. Caspase-3 cleavage was below the level of detection in cells infected with the Ad CMV GFP control vector, chemotherapy or the combination of both. As shown in Figure 5b , similar results were obtained using MS-275 in combination with Ad tetOn TRAIL-IRES-GFP. Combination of depsipeptide with Ad tetOn TRAIL-IRES-GFP also resulted in increased PARP and caspase-3 cleavage (Figure 5b ). PrEC were infected with 70 IU/cell of the control vector Ad tetOn GFP or Ad tetOn TRAIL-IRES-GFP. PARP cleavage was not detected in PrEC treated with depsipeptide or MS-275 either alone or in combination with the control vector (Figure 5c ). Some PARP cleavage was detected following infection with Ad tetOn-TRAIL-IRES-GFP alone but MS-275 did not enhance PARP cleavage. We repeatedly observed a small effect of depsipeptide on enhancing PARP cleavage. However, this effect was not a result of increased TRAIL transgene expression. We also failed to detect fragments corresponding to active caspase-3 under any treatment conditions. The effect of adenoviral TRAIL transgene expression in the absence or presence of HDACi was therefore also evaluated in a caspase-3/7 activity assay. As shown in Figure 6 , an ID 50 of Ad tetOn TRAIL-IRES-GFP used was insufficient to increase caspase-3/7 activity in either LNCaP or PrEC. In combination with depsipeptide, caspase-3/7 activity was higher in LNCaP cells compared to PrEC but levels did not reach statistical significance (P ¼ 0.07) (Figure 6 ). In contrast, combination of Ad tetOn TRAIL-IRES-GFP with MS-275 was significantly higher in LNCaP cells compared to PrEC (Po0.05) ( Figure 6 ). As shown in Figure 7 , results of the caspase-3/7 activity assay corresponded to morphological assessment of the cells.
Discussion
The goal of this study was to determine the effect of chemotherapy on adenoviral gene expression and to identify which chemotherapeutic agent(s) would be the most suitable for combination therapy of prostate cancer. We evaluated the effect of cisplatin, gemcitabine, doxorubicin, depsipeptide and MS-275 on adenoviral infection and transgene expression using GFP as a marker. Cisplatin and gemcitabine did not enhance adenoviral infectivity or GFP transgene expression, while the two HDACi and to some extent doxorubicin increased infectivity and transgene expression in LNCaP cells. Although doxorubicin increased infectivity, we did not detect an increase in TRAIL expression and combination with TRAIL gene therapy failed to enhance PARP and caspase-3 cleavage. These data are in contrast to the sensitizing effect observed when doxorubicin is combined with recombinant TRAIL. 16 Interestingly, overall levels of PARP, which is commonly used as a marker of apoptosis but plays a physiological role as a DNA repair protein, were elevated by doxorubicin. As doxorubicin induces DNA damage, elevated PARP levels may be reflective of an ongoing DNA repair response. In cells treated with cisplatin or doxorubicin, we also detected a The increased transgene expression following chemotherapy was mediated, at least in part, by elevated cell surface expression of CAR. Surprisingly, doxorubicin enhanced surface CAR expression and infectivity to a greater extent in normal PrEC than in LNCaP cells. It is not known whether doxorubicin exerts this effect in vivo, but increasing CAR expression on normal cells would clearly be an undesirable side effect that could lead to increased competition between normal and malignant cells for viral binding. As a result, a higher viral dose may be necessary to achieve a therapeutic benefit.
Several groups, including ours, have shown that HDACi can restore infectivity and transgene expression in CAR negative cells. [12] [13] [14] 19 However, here we show that HDACi can also further increase transgene expression in CAR-positive cells. The ability of HDACi to increase adenoviral transgene expression appears to be limited to malignant cells, since it has not been observed in normal cells isolated from breast, liver, kidney and, as shown in this study, prostate. 20, 21 The success of adenoviral based cancer gene therapy will ultimately depend on whether adenovirus can infect the tumor cells and whether infection is followed by expression of the transgene. CAR, which serves as an adenoviral receptor, plays a physiological role as a tightjunction protein. Lacher et al, 22 recently found that TGF-b-induced epithelial-mesenchymal transformation was accompanied by CAR repression. These findings may explain why decreased CAR expression correlates with tumor aggressiveness and differentiation in bladder and gastrointestinal cancer, respectively.
2,5 A role for CAR as a tumor inhibitor is also supported by the observation that re-expression of CAR resulted in growth inhibition of androgen-independent PC3 prostate cancer cells. 23 Similar results were found in T24 bladder cancer cells. 24 As patients eligible for adenoviral gene therapy trials typically have late-stage disease, epithelial-mesenchymal transformation and loss of CAR may have occurred, which would reduce the potential for a positive therapeutic outcome. Thus, the benefit of HDACi treatment may include reversal of epithelial-mesenchymal transformation and increased CAR expression, which would lead to enhanced adenoviral infectibility and transgene expression.
In this study, we utilized TRAIL gene therapy to demonstrate the potential of combination therapy with HDACi. We found that combination of depsipeptide or MS-275 with TRAIL gene therapy enhanced apoptosis in LNCaP cells as measured by caspase-3 cleavage and activity, PARP cleavage and morphology. In general, MS-275 appeared more potent than depsipeptide, which is similar to observations made in a renal cancer cell line. 20 HDACi can also enhance sensitivity of cancer cells to recombinant TRAIL, which may be mediated by downregulation of anti-apoptotic proteins, upregulation of proapoptotic proteins, increased TRAIL receptor expression and/or facilitation of receptor clustering. [25] [26] [27] [28] Thus combination of systemic HDACi chemotherapy with TRAIL gene therapy may not only have the benefit of selectively enhancing CAR and adenoviral transgene expression but also lowering of the apoptotic threshold in neighboring uninfected cells, which may result in a bystander effect. In summary, our results indicate that combination of TRAIL gene therapy with HDACi, particularly MS-275, may be a novel approach for the treatment of prostate cancer that warrants further investigation.
